A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms DoRIS
- 19 Jun 2017 Status changed from not yet recruiting to recruiting.
- 19 Jun 2017 Planned End Date changed from 1 Aug 2020 to 1 Mar 2021.
- 19 Jun 2017 Planned primary completion date changed from 1 May 2020 to 1 Nov 2020.